Drug Profile
Research programme: antibacterials - Destiny Pharma
Alternative Names: DPD201; DPD202; DPD204; DPD206; DPD207; DPD241; MQ drug series - Destiny Pharma; XF drug series - Destiny Pharma; XF-42; XF-70Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Destiny Pharma
- Class Metalloporphyrins; Porphyrins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Cystic fibrosis; Diabetic foot ulcer; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Cystic-fibrosis in United Kingdom
- 28 Dec 2022 No recent reports of development identified for research development in Diabetic-foot-ulcer in United Kingdom
- 28 Apr 2021 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom (Inhalation)